GNTA

Genenta Science S.p.A. NASDAQ Listed Dec 15, 2021

Healthcare ·Biotechnology ·IT · genenta.com

$0.63

Mkt Cap $12.1M

52w Low $0.59 0.4% of range 52w High $10.00

50d MA $0.76 200d MA $2.01

P/E (TTM) -2.2x

EV/EBITDA -4.3x

P/B 0.7x

Debt/Equity 0.3x

ROE —

P/FCF -3.6x

RSI (14) —

ATR (14) —

Beta 0.71

50d MA $0.76

200d MA $2.01

Avg Volume 96.6K

Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. The company's lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. It is also developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. The company was incorporated in 2014 and is headquartered in Milan, Italy.

SIC Code

2836

CIK (SEC)

1838716

Phone

39 02 26 43 46 81

Via Olgettina No. 58 · Milan, MI 20132 · IT

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Mar 31, 2026	AMC	-0.36	-0.36	+0.0%	0.67	-0.7%	+3.8%	+1.9%	-4.9%	+2.6%	+2.2%	—
Feb 25, 2026	AMC	-0.36	-0.36	+0.0%	1.00	+2.0%	-4.0%	+3.2%	-1.1%	-5.9%	-1.3%	—
Jun 30, 2024	AMC	—	-0.24	—	—	—	—	—	—	—	—	—
Apr 24, 2024	AMC	-0.42	-0.29	+29.7%	2.55	+5.9%	+14.1%	-11.0%	+13.9%	+4.4%	+6.8%	—
Jun 30, 2023	AMC	-0.41	-0.40	+3.3%	5.89	+0.0%	+0.0%	+0.2%	+0.2%	+1.7%	+0.5%	—
Apr 26, 2023	AMC	—	-0.38	—	6.00	+3.2%	+3.2%	-3.1%	+2.7%	+0.6%	+0.0%	—

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Oct 2	HC Wainwright & Co.	Maintains	Buy → Buy	—	$4.08	$4.19	+2.7%	+9.6%	-1.6%	+0.0%	+9.3%	+4.0%
May 13	HC Wainwright & Co.	Maintains	Buy → Buy	—	$3.10	$3.20	+3.2%	+13.2%	-8.3%	-0.6%	-0.6%	+3.8%

Data updated apr 26, 2026 10:43am · Source: massive.com